Experimental group: anlotinib(d1-14, d22-36), followed by 21 days period, 2 weeks medication, 1 week maintenance therapy.
. Group II: 10 mg po qd, Group III: 12 mg po qd;
Combined chemotherapy:
Cisplatin + etoposide Or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + cultured beauty (non squamous cell carcinoma). Synchrotron radiation: radiotherapy combined with radiotherapy (3D-CRT or IMRT) (60-66Gy / day).
The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD.

Patients With Non-small Cell Lung Cancer

Simultaneous chemoradiotherapy for An Luo

The second affiliated Hospital of Xi'an Jiaotong University

Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC

Phase I / II Clinical Study on the Safety and Preliminary Efficacy of Anlotinib Hydrochloride Combined With Platinum-containing Simultaneous Radiotherapy in the Treatment of Locally Advanced Non-small Cell Lung Cancer

complete response(CR)+partial response(PR) according to RECIST 1.1

overall survival is defined as the time from randomization to death from any cause

progression-free survival is defined as the time from enrollment to the date of first document disease progression or death from any cause

Second Affiliated Hospital of Xi'an Jiaotong University

Tang-Du Hospital

Xijing Hospital

First Affiliated Hospital Xi'an Jiaotong University

Shaanxi Provincial Cancer Hospital

Shaanxi Provincial People's Hospital

Experimental group: anlotinib (D1-14, d22-36, followed by 21 days cycle, taking medicine for 2 weeks, stopping for 1 week).
Group 1: 8mg po qd, Group 2: 10mg po qd, Group 3: 12mg po qd;
Combined chemotherapy:
Cisplatin + etoposide or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + pemetrexed (non-squamous cell carcinoma). Simultaneous radiotherapy: 3D-CRT or IMRT external radiotherapy (60-66 Gy, 2.0 Gy / day).
The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD.

The respective palm to be treated with Brimonidine will be randomly assessed and will be matched for handedness to include equal numbers of dominant and non‐dominant treated palms.

Hand-foot Syndrome

1 gram of Brimonidine 3 mg/g gel (Mirvaso®) in 24 hours on the randomized palm equal to a finger tip unit (FTU) of 0.5 gram , topical application under occlusion twice per day, every 12 hours.

Brimonidine Tartrate

Universitätsklinikum Düsseldorf, Klinik für Dermatologie

The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients

Half‐Side Controlled Analysis of the Effect of Topical Brimonidine Tartrate on the Frequency and Severity of Hand‐Foot Syndrome (HFS) in Cancer Patients Receiving Antineoplastic Agents (BRIMOCAN)

Palms with HFS severity of grade 2 or 3 during 2 cycles of chemotherapy or over 6 week period by means of the National Cancer Institute Common Terminology criteria for Adverse Events (NCI‐CTCAE) v4.0 grading

Severity of HFS after 2 cycles of chemotherapy or 6 weeks by means of the NCI‐CTCAE v4.0 grading

Severity of nail toxicity after 2 cycles of chemotherapy or 6 weeks by means of the NCI‐CTCAE v3.0 grading

Severity of HFS after 2 cycles of chemotherapy or 6 weeks by means of a modified Palmoplantar Psoriasis Area Severity Index (ppPASI)

Severity of HFS after 2 cycles of chemotherapy or 6 weeks by means of computer‐assisted quantification

Level of HFS‐associated pain after 2 cycles of chemotherapy or 6 weeks by means of visual analogue scale (VAS)

Highest grade of HFS severity reached until 2 cycle of chemotherapy or over 6 week period by means of the NCI‐CTCAE v4.0 grading

Heinrich-Heine University, Duesseldorf

The respective palm to be treated will be randomly assessed and will be matched for handedness to include equal numbers of dominant and non‐dominant treated palms.

Metastatic Renal Cancer

Prednisone + Everolimus: Everolimus is formulated as tablets of 5-10 mg strength, blister-packed under aluminium foil in units of 10 tablets. Prednisone will be dispensed to patients at the dose of 5 mg twice daily (BID). Everolimus at dose of 10 mg (one 10 mg tablet or two 5 mg tablets). Both drugs will be self-administered orally, continuously from Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death or discontinuation for any other reason.
A treatment cycle consists of 28 days.

Prednisone + Everolimus

U.O Oncologia Medica, IRST IRCCS

Oncologia Medica, PO Faenza, AUSL della Romagna

Oncologia Medica, PO RAVENNA, AUSL della Romagna

Oncologia Medica, PO Rimini-Cattolica, AUSL della Romagna

PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI

Phase II Study of Oral PRednisone 5 mg Bid Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of Vascular Endothelial Growth Factor Receptor-tyrosine Kinase Inhibitors

to evaluate the incidence of grade ≥ 2 stomatitis and non-infectious pneumonitis in RCC patients treated with prednisone 5 mg bid and everolimus 10 mg/day.

the sum of partial responses plus complete responses

time from the date of starting of the treatment to the date of the first observation of documented disease progression or death due to any cause. Patients without tumor progression at the time of analysis will be censored at their last date of tumor evaluation.

time from the date of starting of the treatment to the date of the death due to any cause. Patients living at the time of analysis will be censored at their last date of tumor evaluation.

blister/tyrosine

Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC

The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients

PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI

Täydellisin lääketieteellinen tietokanta tieteen tukemana